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INTRODUCTION
Guillain-Barré syndrome (GBS) has been divided into several subtypes according to clinical, electrophysiological and pathologic findings, infective antecedent and presence of specific antibodies. [1] [2] Two primary axonal subtypes have been described: acute motor axonal neuropathy (AMAN) and acute motor and sensory axonal neuropathy (AMSAN). [3] [4] [5] [6] [7] AMAN and AMSAN have been associated with antecedent Campylobacter jejuni infection and autoantibodies to gangliosides, especially to GM1 and GD1a. [4] [5] [6] [7] [8] [9] AMAN is clinically characterized by exclusive motor involvement although sensory symptoms have been also reported. [3] [4] [10] [11] Immunopathological studies in humans and in the rabbit experimental model indicated that AMAN is due to a complement-mediated attack of anti-ganglioside antibodies to the axolemma of nodes of Ranvier of motor fibres with complement deposition, sodium channel cluster disruption, nodal lengthening, macrophage recruitment and final axonal degeneration in motor fibres. [12] [13] [14] [15] The electrophysiological characteristics of AMAN are absence of demyelinating features and decreased distal compound muscle action potentials (dCMAP). [3] [4] However, reduced dCMAP amplitudes, conduction block (CB) at common entrapment sites or isolated absence of F waves which promptly recover without the development of temporal dispersion or other demyelinating features have been described in some AMAN patients with anti-ganglioside antibodies and ascribed to an antibody-mediated reversible conduction impairment at the axolemma of nodes of Ranvier. [16] [17] [18] AMSAN is quite rare (1-4% of GBS in Japan) eventhough it has been reported up to 11% in Bangladesh. [9, [19] [20] AMSAN is clinically characterized by weakness, areflexia and sensory loss. Most of reported patients had severe weakness requiring mechanical ventilation, inexcitable motor and sensory nerves and poor outcome. [21] [22] [23] In AMSAN, as in AMAN, the pathology is consistent with an antibody-mediated primary axonal damage at the node of Ranvier with the difference that the dorsal, as well as the ventral roots, are affected. [22] [23] However, minor conduction abnormalities in sensory nerves have been reported in 5-12% of AMAN patients blurring the dichotomy between AMSAN and AMAN. [3, 4, 11] Aim of this study was to investigate, by comparing results of serial recordings, whether sensory fibres are completely or relatively spared in AMAN and to verify whether axonal GBS subtypes form a continuous spectrum.
SUBJECTS AND METHODS

Patients
We reviewed the clinical and electrophysiological records of patients diagnosed with GBS at the University Hospital of Chieti between January 1995 and June 2009. Patients were classified as AMAN on the basis of the following criteria: 1) acute onset progressive motor weakness of more than one limb; 2) normal sensory examination; 3) dCMAP amplitudes <80% of lower limit of normal (LLN) in at least two nerves without evidence of demyelination (AMAN with axonal degeneration) or evidence of reversible conduction failure characterized by: reduced dCMAP amplitude with normal or slightly prolonged distal motor latencies (DMLs) and/or partial CB (defined as an amplitude ratio of CMAPs from proximal and distal stimulation less than 0.5) in intermediate nerve segments which, at serial recordings, recovered within 6 weeks without developing temporal dispersion (increased duration of negative peak of proximal CMAP >30% compared with dCMAP) or conduction slowing (AMAN with reversible conduction 6 failure); 4) normal or reduced sensory nerve action potential (SNAP) amplitudes not fulfilling the criteria for diagnosis of AMSAN. [5, 16, 22, [24] [25] Patients were classified as AMSAN on the basis of the following criteria: 1) acute onset progressive motor weakness of more than one limb and loss of at least one sensory modality; 2) results of motor nerve conduction studies as in AMAN; 3) SNAP amplitude <50% of LLN in at least two nerves. [5, 22] The final electrodiagnosis was based on the results of sequential studies and considering the whole electrophysiological history in each patient.
Electrophysiological studies
Motor conduction studies of median, ulnar, peroneal and tibial nerves were performed as previously reported. [25] Amplitude and duration of negative peak of dCMAP and CMAP from proximal stimulation (pCMAP), conduction velocities (CV), distal motor latencies (DMLs) and minimal F-wave latencies were measured.
For sensory conductions, median and ulnar nerves were stimulated at the proximal wrist crease and sensory nerve action potentials (SNAPs) were antidromically recorded by ring electrodes placed at the interphalangeal joints of the third and fifth digit respectively. In selected patients median nerves were also stimulated at elbow, ulnar nerves were stimulated below elbow and above elbow, and SNAP amplitude ratios were calculated. Sural nerve was stimulated at the lateral malleolus and SNAP recorded orthodromically by a bar electrode placed slightly lateral to the midline in the lower third of the posterior aspect of the leg. 
Definition of significant changes in serial sensory conduction studies
To evaluate the extent of variation in serial recordings of SNAP amplitudes we made a test-retest study in 20 volunteers (median age 55 years, range 23-87). In each subject, median, ulnar and sural nerve conductions were repeated one week apart by four examiners for a total of 480 recordings. We determined the rootmean-square percent coefficient of variation (RMS-%CV) of SNAP amplitude and calculated the least significant change (LSC), i.e the minimum difference between two results that can be considered to reflect a true change at a 95% statistical confidence level. The LSC was calculated by the formula: RMS-%CV x 2.77. [26] SNAP amplitudes were considered significantly increased or decreased compared to a precedent study when the value varied by at least 44% for median nerve, 47% for ulnar nerve and 58% for sural nerve.
Anti-ganglioside antibody testing
IgG and IgM to gangliosides GM1, GD1a and GD1b were tested by ELISA as previously described. [27] 
RESULTS
Clinical and laboratory findings
From a series of 116 consecutive GBS patients, thirteen patients diagnosed with AMAN and three diagnosed with AMSAN had at least two examinations of motor and sensory conductions in the same nerves within 5 months from onset and an optimal quality of sensory recordings, and were considered for the present study (Table 1) . Twelve patients were men (75%). Median age was 63 years (range 17-81). All patients presented with symmetric limb weakness.
In the AMAN group, paresthesia were present in 2 of 13 (15%) and pain in 4 of 13 (31%) patients. Deep tendon reflexes (DTR) were absent or hypoactive and absent distally in eight patients, preserved (diffusely hypoactive or normal) in four, and brisk in one. One patient had dysphagia, none had respiratory failure or dysautonomia. CSF examination showed albumino-cytological dissociation in 11 patients. Nine patients were treated with IVIg (2 g/kg in 5 days), the remainders received a course of 3-5 plasmaphereses. 
Electrophysiological findings
Baseline electrophysiological examination was performed within 15 days from onset of symptoms (median: 7 days; range: 2-15) in at least three motor and three sensory nerves. The second test was performed 2-18 days after the first examination in 13 patients, and 37-146 days after the first examination in three patients. Eight patients received further evaluations. Patients 2, 8, 15 and 16 who were admitted when this study was already in course, were prospectively studied for motor and sensory conductions. The total number of electrophysiological examinations was 48. The total number of sensory nerves reexamined in subsequent recordings was 47.
Following are the results of serial electrophysiological studies. For clearness sake we present electrophysiological findings by dividing patients in four groups: AMAN with axonal degeneration, AMAN with reversible conduction failure, AMAN with axonal degeneration and minor sensory abnormalities, and AMSAN. Serial sensory conduction studies are fully reported in Table 2 in order to make easier to follow description and summary of results .
AMAN with axonal degeneration
In patients 1-8, baseline electrophysiological examination showed dCMAP amplitudes < 80% of LLN in at least two nerves and no signs of demyelination. In subsequent recordings, dCMAP remained stable or further decreased and moderate to abundant fibrillation potentials were found. In patients with longterm follow-up, improvement of dCMAP amplitude was seen by weeks (median: 20 weeks). These patients had normal sensory studies at baseline and were classified as AMAN with axonal degeneration pattern.
In Patients 1 and 2, sensory conductions did not substantially change at follow-up. Six patients (Patients 3-8) showed significant changes in SNAP amplitude in re-tested nerves (Table 2 ). In particular, in Patients 3 and 4, median nerve SNAP decreased by 50-69% and become abnormal within the three weeks after onset (Fig 1A) . In Patient 5, SNAP amplitude of the right ulnar, median and sural nerves significantly increased within 4 weeks from onset up to 518% of the baseline value (Fig 1B) . In Patients 6 and 7, the amplitude of sural SNAP increased by 207% at day 52 after onset and by 138% at day 102 respectively. In Patient 8, left ulnar SNAP amplitude decreased by 64% nine days after onset to recover in 80 days and be increased by 57% compared to baseline at day 191.
SNAP amplitude of left median nerve gradually increased by 59% compared to baseline, and SNAP amplitude of right median and ulnar nerves was found significantly increased by 63-105% at day 191 (Fig 1C) .
AMAN with reversible conduction failure
Patients 9,10,11 showed, at the baseline electrophysiological examination, lowamplitude dCMAPs in at least two nerves, mildly prolonged DML in six nerves (median: 122% of ULN; range: 109-132) and partial motor CB in nine nerves.
MCV was normal except for the site of CB in five nerves. Within six weeks amplitude and latency of dCMAPs normalized, CB and conduction slowing at the site of CB resolved without development of excessive temporal dispersion of CMAPs. At follow-up, little or no signs of denervation were seen at EMG. These three patients, classified as AMAN with reversible conduction failure pattern, had normal sensory studies at the first examination performed within the first week. [16, 23] In the left median nerve of Patient 9, SNAP amplitude increased by 220% in eight weeks along with normalization of dCMAP amplitude, whereas proximal SNAP amplitude increased by 139% along with improvement of proximal CMAP amplitude and disappearance of motor CB (Fig 2) . At day 23, because of the greater increase of SNAP amplitude from wrist stimulation compared to SNAP from elbow stimulation, the SNAP ratio decreased from 0.75 to 0.42. The SNAP ratio increased to 0.56 at day 59. In the remaining two patients no significant changes were observed in SNAPs, and SNAP ratios remained within the normal range throughout the follow-up. In Patient 13, who had at baseline only abnormal median SNAP amplitude and SCV (respectively 73% ad 88% of LLN), the re-examination five months after onset showed, in the median nerve, the persistence of low-amplitude SNAP but normalization of SCV, whereas there was a significant decrease of SNAP amplitude in sural nerve (-61%) and a non significant decrease of SNAP amplitude in ulnar nerve (by 42%). At 9 months median nerve SNAP was increased by 128% compared to baseline becoming normal.
AMAN with axonal degeneration and minor sensory abnormalities
AMSAN
Three patients (Patients 14-16) had dCMAP amplitudes < 80% of LLN in at least two nerves, SNAP amplitude <50% of LLN in at least two nerves, and were classified as AMSAN. Patient 14 showed no significant changes of motor and sensory conductions during the first two weeks.
In Patient 15, baseline CMAP amplitudes were markedly decreased in both median and ulnar nerves and at lower limit of normal in peroneal nerves, whereas SNAP amplitudes were < 50% of LLN in both ulnar nerves and normal in both median nerves and in right sural nerve. At follow-up, distal CMAP disappeared or further decreased in amplitude in upper limb nerves, remained stable in left peroneal nerve and improved by 59% in right peroneal nerve by day 55. Conversely, SNAP amplitude of ulnar nerves significantly improved by 150-300% and normalized within one week during IVIg administration (Fig 3) . (Fig 4) .
Summary of serial sensory conduction findings
In the AMAN group, one sensory nerve showing minor abnormalities at baseline significantly recovered at follow up, and 11 of 32 initially normal sensory nerves (34%) of 6 patients (five with baseline normal sensory conductions, one with minor sensory abnormalities at baseline) showed an increase of SNAP amplitude (median increase by 106%, range 57-518%). Conversely, in three initially normal nerves of three AMAN patients (two with baseline normal sensory conductions, one with minor sensory abnormalities at baseline) a decrease of SNAP amplitude was found (median decrease by 60%, range 50-69). In summary, in the AMAN group we found that: 1) two patients had minor sensory changes in three nerves at baseline; 2) 14 of 32 initially normal nerves (44%) and seven of 11 patients with baseline normal sensory conductions (64%) showed significant changes in SNAP amplitude; 3) overall sensory fibres were involved in 49% of nerves and in 69% of AMAN patients.
In one AMSAN patient, SNAP amplitude increased by 150-300% in two nerves. In six nerves of another AMSAN patient, SNAPs were unrecordable at baseline but reappeared during follow-up normalizing in three nerves.
Overall eleven of 16 patients with axonal GBS (69%) showed significant changes in SNAP amplitudes in 23 of 47 (49%) re-tested nerves (Table 1 and   Table 2 ).
Antiganglioside antibodies
Antibodies to at least one of the examined gangliosides were found in 13 of 15 tested patients (87%) ( Table 1 ). There was no difference in the immunological profile of AMAN and AMSAN patients. Anti-GD1b antibodies were not associated with paresthesias (p=0.026), pain (p=0.315), sensory loss (p=0.077), electrophysiological involvement of sensory fibres at baseline (p=0.119) or at follow-up (p=1.000).
DISCUSSION
Axonal GBS is a term derived from pathology but electrophysiologically defined axonal GBS subtypes are not only the expression of axonal degeneration. Three AMAN and one AMSAN patients we report showed at serial recordings reversible conduction failure in motor fibres. Reversible conduction failure, described in some patients with anti-ganglioside antibodies and in a GBS subtype named acute motor conduction block neuropathy, is ascribed to an antibody-mediated reversible conduction impairment at the axolemma of nodes of Ranvier. [16, 28] According to experimental studies, anti-ganglioside antibodies attack primarily the axolemma of motor fibres at the nodes of Ranvier sequentially inducing complement activation, disruption of sodium channel clusters and nodal architecture and finally Wallerian-like degeneration. [15] In some patients, this pathological cascade may arrest to the stage of sodium channel derangement resulting in transient and reversible failure of axonal function. [2] The occurrence of reversible conduction failure in motor fibres has not been reported in AMSAN before and may explain why some AMSAN patients do not have poor outcome.
The 13 patients with AMAN we report had clinically pure motor GBS with no sensory signs. DTR were preserved in four patients and brisk in one.
According to Asbury and Cornblath (1990) universal areflexia is the rule in GBS although distal areflexia with definite hyporeflexia of the biceps and knee jerks will suffice for diagnosis if other features are consistent. [29] DTR may be preserved throughout the disease course in patients with AMAN. [30] Moreover, 48% of Chinese and 33% of Japanese patients with AMAN showed hyperreflexia in the recovery phase. [16, 31] Moderate weakness and the normal afferent branch of the myotatic reflex arch could account in our patients for the preservation of DTR but they do not explain hyperreflexia. Electrophysiologic evidence of lower motor neuron hyper-excitability has been reported in some patients with AMAN with hyperreflexia. [32] [33] In conclusion, preserved DTR and even hyperreflexia may occur in patients with AMAN and are not inconsistent with the diagnosis.
Paresthesia was present in 15% and pain in 31% of patients. Two patients (15%) had mild sensory abnormalities at baseline electrophysiological examination. As for preserved DTR, these features are not inconsistent with AMAN diagnosis.
Paresthesia has been reported in 10-40 % of patients and pain, even severe, accompanies AMAN in up to 66% of patients. [3, 10, 11, 34] The sensory conduction abnormalities we found at baseline in two patients did not satisfy the electrophysiological criteria to define AMSAN, and have been reported in 5-12% of AMAN patients. [3, 4, 5, 11, 22] Serial recordings of sensory conductions demonstrated that sensory fibres were subclinically involved in most AMAN patients, even when baseline sensory conductions appeared normal. In fact, SNAP amplitudes significantly increased in 34% of initially normal nerves of 6 patients indicating that, at baseline, sensory fibres were involved although not enough to produce a decrease of SNAP below the LLN. Similarly, in eight nerves of two AMSAN patients initially absent or reduced SNAPs recovered at follow-up. In three AMAN patients, SNAP amplitude decreased in three initially normal nerves indicating a later involvement of sensory fibres. Overall, in our series, baseline and subsequent serial recordings allowed to detect sensory fibres involvement in 49% of nerves and in 69% of AMAN patients.
The improvement of SNAPs followed two courses. In five nerves of three AMAN and in eight nerves of two AMSAN patients SNAP amplitudes increased rapidly (within 2-4 weeks from onset). Similar features have been reported in one AMAN patient with reversible conduction failure pattern and antibody to GM1/GalNAc-GD1a complex and in patients with acute sensory ataxic neuropathy and antibodies to GD1b suggesting that reversible conduction failure may occur not only in motor but also in sensory fibres. [35, 36] In other patients, SNAP amplitudes increased over months according to an axonal regeneration process.
We did not found different immunological profiles in electrophysiologically pure motor GBS, AMAN with minor sensory involvement, and AMSAN. In particular, we could not confirm the hypothesis that anti-GD1b antibodies were associated with clinical or electrophysiological involvement of sensory fibres.
Although our findings demonstrate that AMAN is not an exclusively motor neuropathy, there is no doubt that the involvement of motor fibres is predominant and determinant for clinical severity. The bases of this phenomenon are not clear. Biochemical studies demonstrated that sensory and motor nerves express similar quantities of GM1 and GD1a gangliosides. [37, 38] However, serum from an AMAN patient with anti-GD1a antibodies selectively stained nodes of Ranvier of motor fibres and an anti-GD1a monoclonal antibody (mAb) preferentially stained motor spinal roots in humans and rodents. [38, 39] A study employing several mAbs and GD1a derivates suggested that both fine specificity of antibodies and different orientation/exposure of ganglioside in motor and sensory fibres contribute to target recognition by anti-ganglioside antibodies. [40] Moreover a number of biophysical differences between human sensory and motor axons have been reported. Sensory axons have less supernormality and late subnormality, longer strength-duration time constant and a lower rheobase than motor nerves. [41] [42] [43] [44] Sensory axons accommodate more than motor axons to long-lasting hyperpolarizing currents suggesting a greater expression of the hyperpolarization-activated inward rectifier channels and greater expression of persistent Na+ channels. [42, 45] Lastly, the electrogenic Na + -K + -ATPase is more active in sensory nerves. [46] These differential biophysical features may explain the fact that motor fibres are more affected than sensory fibres by the attack of the same antibody and the coexistence of positive sensory symptoms such as paresthesias in some AMAN patients.
Whatever is the reason of differential involvement of motor and sensory fibres in axonal GBS subtypes this study shows that: 1) sensory fibres are involved in AMAN although to a lesser extent than motor fibres and not enough to 
